This webcast is based on a roundtable discussion on the optimal diagnosis and future management of lysosomal diseases. Three experts specializing in Fabry, Gaucher, and Pompe disease will raise key clinical questions and discuss how to overcome barriers in daily clinical practice across the lysosomal disease spectrum. The experts will provide an update on the long-term effects of ERT and highlight the remaining challenges, including the consequences of delayed diagnosis. They will discuss the role and importance of early diagnosis and treatment initiation, and provide perspectives on the recent advances in screening programs for newborn and high-risk populations. Lastly, the experts will address the position of emerging therapies and strategies for the optimal management of lysosomal diseases.
Look no further for the most cutting edge cardiology CME courses. We offer cardiology continuing medical education courses in dyslipidemia, acute coronary syndrome (acs), and Morquio A Syndrome, among others.
AN UPDATE ON EMERGING S1P THERAPEUTICS FOR THE MANAGEMENT OF PATIENTS WITH RELAPSING MULTIPLE SCLEROSISFormat: Conference Reporter
This CME program will highlight data presented at the 7th Annual Joint ECTRIMS – ACTRIMS Meeting in Paris, France. The three expert faculty will analyze recent therapeutic advances in the treatment and management of multiple sclerosis (MS). The clinical relevance of emerging and emerged trial data, particularly regarding S1P therapeutics, will be assessed. Faculty will outline strategies for utilizing the multidisciplinary team approach to develop and implement data-driven, tailored treatment plans in clinical practice. Upon completion of this CME activity, learners will have a better grasp of evolving science in the field of MS in order to improve outcomes and quality of care.
The content for this activity is derived from a live symposium titled, “Applying PCSK9 Inhibitors to Optimize Outcomes in Patients With Dyslipidemia” presented at the American Heart Association Scientific Sessions 2017 in Anaheim, California. This CME activity will highlight optimal treatment and management strategies for patients with dyslipidemia in the era of PCSK9 inhibitors. The expert faculty will review recent clinical trial and CVD outcomes data, encompassing lipid lowering therapies for the diabetic patient subset. Dyslipidemia guidelines as well as strategies for achieving LDL-C goal will be outlined, particularly in the high-risk population. Dr. Christopher P. Cannon and the accompanying faculty will utilize an interactive panel format to translate evidence-based medicine to optimal clinical decision making. This CME program will provide cardiologists with vital information for improving healthcare outcomes in patients with dyslipidemia.
AHA 2017: APPLYING PCSK9 INHIBITORS TO IMPROVE OUTCOMES AND THE OVERALL QUALITY OF LIFE FOR PATIENTS WITH DYSLIPIDEMIAFormat: Conference Reporter
This Elsevier Conference Reporter will cover data presented at the American Heart Association (AHA) Scientific Session 2017 held in Anaheim, CA. The expert faculty will discuss the role of PCSK9 inhibitors for the treatment of dyslipidemia including achieving LDL-C goals, cardiovascular risk reduction and managing special patient populations. Current and emerging clinical trial data of PCSK9 inhibitors will be analyzed. The faculty will discuss different approaches of how to implement newer therapies into individualized treatment plans. Upon completing this activity, clinicians will gain a better understanding of treatment options to provide better outcomes for patients with dyslipidemia.
RAISING THE BAR BY LOWERING THE TARGET Integrating PCSK9 Inhibitors into Hypercholesterolemia ManagementFormat: Resource Center
This CME-accredited CME Snapshot™ seven-part series is intended for interventional cardiologists, other cardiologists, lipidologists, endocrinologists, and other diabetologist physicians involved in the ongoing management of patients with persistent hypercholesterolemia.
During these quick-hitting activities, expert faculty will participate in a series of interactive discussions on the latest evidence and their clinical experience managing patients with persistently elevated low-density lipoprotein cholesterol (LDL-C) levels using nonstatin lipid-lowering medications, including inhibitors of the enzyme protein convertase subtilisin/kexin type 9 (PCSK9). Physicians can complete all 7 video modules for a total of 2.0 AMA PRA Category 1 Credits™.
This webcast was recorded during a live symposium at the WORLDSymposium Meeting in San Diego, CA, USA, on February 7, 2018. During the symposium, experts from around the world discussed the key clinical questions and controversies in the diagnosis of Fabry disease and the future direction of clinical management. They also addressed the consequences of delayed diagnosis and treatment initiation, provided guidance on understanding available diagnostic options, and discussed genotype–phenotype correlations and their significance for daily clinical practice.
This activity will focus on the most current clinical trial data for achieving LDL-C goal for all patients in the era of PCSK9 inhibitors as presented as an Unofficial Satellite Event at the American Heart Association Scientific Sessions 2016. The expert faculty utilize an interactive panel format to translate evidence-based medicine to optimal clinical decision-making. The educational material of this symposium will provide information that every cardiologists needs to know to improve healthcare outcomes in their patients with cardiovascular disease.